Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AbCellera (Nasdaq: ABCL) presented new findings on its T-cell engager (TCE) platform at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The data highlighted the company's novel CD3-binding antibodies, revealing their superior binding and functional characteristics compared to existing antibodies used in TCE development. Key findings include the ability to create optimized TCEs designed for various tumor types, showcasing high potency and minimal cytokine release from engineered TCEs. Additionally, AbCellera reported the discovery of antibodies targeting the MAGE-A4 peptide-MHC complex, which may enable treatment of solid tumors while minimizing impact on healthy tissue. The advancements in AbCellera's platform aim to expedite the development of effective cancer therapies.
AbCellera (Nasdaq: ABCL) has announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference to be held in Toronto on April 25, 2023. The presentation is scheduled for 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time). A live audio webcast of the event will be available on AbCellera's Investor Relations website, with a replay accessible after the presentation.
AbCellera is pioneering advancements in antibody drug discovery, aiming to deliver superior medicines to patients faster. The company's integrated approach combines expert teams and innovative technology to streamline the drug development process, offering significant advantages to biotech firms and pharmaceutical companies.
AbCellera (Nasdaq: ABCL) is set to announce its first quarter 2023 financial results on May 4, 2023, at 2:00 p.m. PT (5:00 p.m. ET). An earnings conference call will follow, accessible via a live audio webcast available on AbCellera’s Investor Relations website.
AbCellera is redefining antibody drug discovery by integrating expert teams, technology, and data science, accelerating the journey from target identification to clinical application. This innovative approach aims to enhance drug development efficiency for both biotechs and pharmaceutical companies.
AbCellera (Nasdaq: ABCL) has formed a strategic collaboration with RQ Bio to develop therapeutic candidates targeting infectious diseases, including influenza and cytomegalovirus (CMV). This partnership aims to leverage RQ Bio's expertise in viral evolution alongside AbCellera's antibody discovery engine. Under the agreement, RQ Bio will have the rights to develop and commercialize resulting therapeutic antibodies, while AbCellera will receive research payments and potential milestone payments and royalties on net sales. This collaboration is anticipated to advance the development of effective medicines for high-risk patients.